Phase 3Completed
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea
Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial
- Sponsor
- Novo Nordisk A/S (Industry)
- Enrollment
- 359 enrolled
- Conditions
- Metabolism and Nutrition Disorder; Obesity; Obstructive Sleep Apnoea
- Interventions
- liraglutide; placebo
- Ages
- adults
- Registry
- NCT01557166
Full record on ClinicalTrials.gov
From the registry
This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.
Primary outcomes
- Change From Baseline in Apnoea-hypopnoea Index (AHI)
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered